CLS Holdings plc (LON:CLI – Get Free Report) declared a dividend on Tuesday, April 1st, DividendData.Co.Uk reports. Stockholders of record on Thursday, April 10th will be paid a dividend of GBX 2.68 ($0.03) per share on Friday, May 23rd. This represents a dividend yield of 4.17%. The ex-dividend date of this dividend is Thursday, April 10th. This is a 3.1% increase from CLS’s previous dividend of $2.60. The official announcement can be seen at this link.
CLS Stock Performance
Shares of CLI opened at GBX 62.89 ($0.80) on Tuesday. CLS has a one year low of GBX 60.91 ($0.78) and a one year high of GBX 101.40 ($1.29). The company has a market cap of £250.61 million, a PE ratio of -1.21 and a beta of 1.01. The stock has a 50-day moving average of GBX 71.06 and a 200-day moving average of GBX 80.91. The company has a debt-to-equity ratio of 123.30, a current ratio of 0.73 and a quick ratio of 0.59.
CLS (LON:CLI – Get Free Report) last announced its quarterly earnings data on Tuesday, April 1st. The company reported GBX (23.60) (($0.30)) EPS for the quarter. CLS had a negative net margin of 134.11% and a negative return on equity of 23.42%. On average, equities research analysts predict that CLS will post 10.0104167 EPS for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Analysis on CLS
CLS Company Profile
We are a commercial property investment company with a £2.1bn portfolio listed on the Premium Main Market on the London Stock Exchange, specialising in future-focused office space in the UK, Germany and France. Through geographical diversification, local expertise and an active management approach, we transform office properties into sustainable, modern spaces that help our tenants’ businesses to grow.
Featured Articles
- Five stocks we like better than CLS
- 3 Fintech Stocks With Good 2021 Prospects
- Who Led Buybacks to End 2024? Hint: It Wasn’t Big Tech
- What is the Nasdaq? Complete Overview with History
- Alibaba Caught in Tariff Crossfire: Is It Time to Buy?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Can Solid Biosciences Challenge Sarepta in the DMD Market?
Receive News & Ratings for CLS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CLS and related companies with MarketBeat.com's FREE daily email newsletter.